NMLSF (Restart Life Sciences) Debt-to-Equity: 0.23 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Restart Life Sciences Debt-to-Equity?

Restart Life Sciences NMLSF +14.03% Debt-to-Equity is 0.23 as of Mar. 2026. The stock has 3 warning signs investors should review. Among 966 Biotechnology companies, Restart Life Sciences ranks worse than 58.07% on this metric.

Restart Life Sciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2026 was $0.25 Mil. Restart Life Sciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2026 was $0.01 Mil. Restart Life Sciences's Total Stockholders Equity for the quarter that ended in Mar. 2026 was $1.13 Mil. Restart Life Sciences's debt to equity for the quarter that ended in Mar. 2026 was 0.23.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Restart Life Sciences's Debt-to-Equity or its related term are showing as below:

NMLSF' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.27   Med: -0.06   Max: 0.23
Current: 0.23

During the past 13 years, the highest Debt-to-Equity Ratio of Restart Life Sciences was 0.23. The lowest was -0.27. And the median was -0.06.

NMLSF's Debt-to-Equity is ranked worse than
58.07% of 966 companies
in the Biotechnology industry
Industry Median: 0.16 vs NMLSF: 0.23

Restart Life Sciences  (OTCPK:NMLSF) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Restart Life Sciences Debt-to-Equity Related Terms

Restart Life Sciences Debt-to-Equity Historical Data

* Premium members only.

The historical data trend for Restart Life Sciences's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Restart Life Sciences Debt-to-Equity Chart

Restart Life Sciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 -0.27 0.19

Restart Life Sciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.19 0.23

NMLSF vs VRTX, REGN, RVMD: Debt-to-Equity Comparison

For the Biotechnology subindustry, Restart Life Sciences's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Restart Life Sciences Debt-to-Equity vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Restart Life Sciences's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Restart Life Sciences's Debt-to-Equity falls into.


Restart Life Sciences Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Restart Life Sciences's Debt to Equity Ratio for the fiscal year that ended in Dec. 2025 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.178 + 0) / 0.933
=0.19

Restart Life Sciences's Debt to Equity Ratio for the quarter that ended in Mar. 2026 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.248 + 0.01) / 1.125
=0.23

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Equity →
What does a Debt-to-Equity of 0.23 mean?
Restart Life Sciences (NMLSF) has a Debt-to-Equity of 0.23 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Restart Life Sciences and its competitors. According to the industry distribution chart, Restart Life Sciences ranks #561 out of 966 companies in the Biotechnology industry, placing it in the top 58.1%.
Is Restart Life Sciences' Debt-to-Equity too high?
Restart Life Sciences' current Debt-to-Equity is 0.23. The Biotechnology industry median Debt-to-Equity is 0.16. Restart Life Sciences' value of 0.23 is 43.8% above this industry median. Based on the distribution chart, Restart Life Sciences ranks #561 out of 966 companies in the Biotechnology industry, which is below the industry midpoint.
How does Restart Life Sciences' Debt-to-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Restart Life Sciences ranks #561 out of 966 companies for Debt-to-Equity. This places Restart Life Sciences in the lower half of its industry. The industry median Debt-to-Equity is 0.16. Restart Life Sciences' value of 0.23 is 43.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 966 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Restart Life Sciences's current Debt-to-Equity of 0.23 is 43.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Restart Life Sciences and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Restart Life Sciences's current Debt-to-Equity is 0.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Restart Life Sciences stock overvalued right now?
Restart Life Sciences (NMLSF) has a current Debt-to-Equity of 0.23. The current Debt-to-Equity is 0.23 and 43.8% above the Biotechnology industry median of 0.16. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Restart Life Sciences (NMLSF), the current Debt-to-Equity is 0.23 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Restart Life Sciences Business Description

Other Exchanges HEAL:Canada
Address 700 - 838 West Hastings Street, Vancouver, BC, CAN, V6C 0A6
Restart Life Sciences Corp is a Canadian-based life sciences company dedicated to addressing health challenges with wellness solutions. Its brands include HolyCrap, BrainQ, Brain Balls.